NCT06758700

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Conditions

• Extensive-stage Small Cell Lung Cancer (ES-SCLC)
• Thoracic Neoplasms
• Lung Neoplasms
• Lung Diseases

Interventions

Type	Name	Description
DRUG	Teniposide administration	Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 3-5 consecutive days, with 21 days as one cycle of treatment.

Timeline

• Start date: 2025-02-07
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2025-01-06
• Last updated: 2025-12-05

Locations

1 site across 1 country: China